Commercial influence and global nongovernmental public action in health and pharmaceutical policies

International Journal of Health Services

Volumn 41, Issue 3, 2011, Pages 539-563

  Koivusalo, Meri ^a   MacKintosh, Maureen ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

COMMERCIALIZATION; CORPORATE STRATEGY; DEVELOPING WORLD; GLOBAL PERSPECTIVE; HEALTH CARE; HEALTH POLICY; NONGOVERNMENTAL ORGANIZATION; PHARMACEUTICAL INDUSTRY; POLICY MAKING; TRADE POLICY;

ARTICLE; DEVELOPING COUNTRY; DRUG CONTROL; DRUG INDUSTRY; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNATIONAL COOPERATION; INTERVIEW; MANAGEMENT; METHODOLOGY; ORGANIZATION AND MANAGEMENT; POLITICS; PUBLIC HEALTH SERVICE; PUBLIC RELATIONS; SOCIAL BEHAVIOR; WORLD HEALTH ORGANIZATION;

DEVELOPING COUNTRIES; DRUG AND NARCOTIC CONTROL; DRUG INDUSTRY; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; INTERINSTITUTIONAL RELATIONS; INTERNATIONALITY; INTERVIEWS AS TOPIC; POLICY MAKING; POLITICS; PUBLIC HEALTH PRACTICE; SOCIAL RESPONSIBILITY; WORLD HEALTH ORGANIZATION;

EID: 80052143489     PISSN: 00207314     EISSN: 15414469     Source Type: Journal    
DOI: 10.2190/HS.41.3.h     Document Type: Article

References (81)

1. t'Hoen, E. TRIPS, pharmaceutical patents, and access to essential medicines: A long way from Seattle to Doha. Chicago J. Int. Law 3:27-46, 2002.
2. Sell, S. TRIPS and the access to medicines campaign. Wisconsin Law J. 20(3): 481-522, 2002.
3. Sell, S. The quest for global governance in intellectual property and public health: Structural, discursive, and institutional dimensions. Temple Law Rev. 77:363-400, 2004.
4. Sell, S. Books, Drugs and Seeds: The Politics of Access. Paper presented for the Transnational Consumer Dialogue, Brussels, March 20-21, 2006, and ISA Conference in San Diego, 2006. http://research.allacademic.com/one/www/research (accessed April 1, 2009).
5. Sell, S. K., and Prakash, A. Using ideas strategically: The contest between business and NGO networks in intellectual property rights. Int. Stud. Q. 48:143-175, 2004. (Pubitemid 38345739)
6. Velasquez, G., Correa, C., and Balasubramaniam, T. WHO in the frontlines of the access to medicines battle: The debate on intellectual property rights and public health. In Intellectual Property in the Context of the WTO TRIPS Agreement: Challenges to Public Health, ed. J. A. Z. Bermudez and M. A. Oliveira. WHO/PAHO Collaborative Center for Pharmaceutical Policies, National School of Public Health Sergio Arouca, Oswaldo Cruz Foundation, Rio de Janeiro, 2004. http://www.law.fsu.edu/gpc2007/materials/LivroTRIPSEnglish2004.pdf (accessed April 2009).
7. Bond, P. Globalization, pharmaceutical pricing, and South African health policy: Managing confrontation with U.S. firms and politicians. Int. J. Health Serv. 29(4): 765-792, 1999.
8. Matthews, D. The role of international NGOs in the intellectual property policy-making and norm-setting activities of multilateral institutions. Chicago-Kent Law Rev. 82(3):1369-1387, 2007.
9. Matthews, D. NGOs, Intellectual Property Rights, and Multilateral Institutions. Report of the IP-NGOs project. Queen Mary Intellectual Property Research Institute, London, 2006.
10. Cullet, P. Patents and medicines: The relationship between TRIPS and the human right to health. Int. Aff. 79(1):139-160, 2003.
11. Matthews, D. WTO decision on implementation of paragraph 6 of the Doha Declaration on the TRIPS Agreement and public health: A solution to the access to essential medicines problems. J. Int. Econ. Law 7(1):73-107, 2004. (Pubitemid 38317901)
12. Thomas, C., and Weber, M. The politics of global governance: Whatever happened to Health for All by the year 2000? Global Governance 10:187-205, 2004. (Pubitemid 38789449)
13. Kickbush, I. The development of international health policies? accountability intact? Soc. Sci. Med. 51:979-989, 2000.
14. Ollila, E. Restructuring global health policy-making: The role of global public-private partnerships. In Commercialisation of Health Care: Global and Local Dynamics and Policy Responses, ed. M. Mackintosh and M. Koivusalo. Palgrave/Macmillan, Basingstoke, UK, 2005.
15. Ollila, E. Global health priorities - priorities of the wealthy? Globalization Health 1(1):6, 2005. http://www.globalizationandhealth.com/ content/1/1/6.
16. Seckinelgin, H. The multiple worlds of NGOs and HIV/AIDS: Rethinking NGOs and their agency. J. Int. Dev. 18:715-727, 2006. (Pubitemid 44088817)
17. Seckinelgin, H. Time to stop and think: HIV/AIDS, global civil society, and people's politics. In Global Civil Society, ed. M. Glasius, M. Kaldor, and H. Anheier. Oxford University Press, Oxford, 2002.
18. Hein, W., and Kohlmorgen, L. Global health governance: Conflicts on social rights. Global Soc. Policy 8:80-108, 2008.
19. Hein, W., Bartsch, S., and Kohlmorgen, L. Global Health Governance and the Fight against HIV/AIDS. Palgrave/Macmillan, New York, 2007.
20. Buse, K., and Walt, G. Global public-private partnerships for health. Part I: New development in health. Bull. World Health Organ. 78(4):549-561, 2000. (Pubitemid 30367620)
21. Buse, K., and Walt, G. Global public-private partnerships for health. Part 2: What are the health issues for global governance? Bull. World Health Organ. 78(5):699-799, 2000.
22. Buse, K. Governing public-private partnerships. Brown J. World Aff. 10(2):225-242, 2004.
23. Buse, K., and Harmer, A. Seven habits of highly effective global public private-partnerships: Practice and potential. Soc. Sci. Med. 64(2):259-271, 2007. (Pubitemid 44894664)
24. Buse, K., and Harmer, A. Power to the partners? The politics of public-private partnerships. Development 47(2):49-56, 2004. (Pubitemid 39182477)
25. Doyle, C., and Patel, P. Civil society organisations and global health initiatives: Problem of legitimacy. Soc. Sci. Med. 66(9):1928-1938, 2008. (Pubitemid 351446080)
26. Richter, J. Public-Private Partnerships and International Health Policy-Making: How Can Public Interests Be Safeguarded? Ministry for Foreign Affairs of Finland, Helsinki, 2004. Shortened version, as policy brief, at http://www.gaspp.org.
27. Keck, M., and Sikkink, K. Activists beyond Borders: Advocacy Networks in International Politics. Cornell University Press, Ithaca, NY, 1998.
28. World Health Organization. Report of the Second Meeting of Interested Parties. WHO Action Programme on Essential Drugs and Vaccines. Geneva, 1988. http://whqlibdoc.who.int/HQ/1988/WHO-DAP-88.12.pdf
29. Olesen, T. In the court of public opinion: Transnational problem construction in the HIV/AIDS medicine access campaign 1998-2001. Int. Sociol. 21(5):5-30, 2006.
30. Chaudhuri, S. Is product patent protection necessary to spur innovation in developing countries? In The Development Agenda: Global Intellectual Property and Developing Countries, ed. N. W. Netanel. Oxford University Press, Oxford, 2009.
31. Amsterdam Statement to WTO Member States on Access to Medicine, Amsterdam, November 25-26, 1999. http://www.cptech.org/ip/health/ amsterdamstatement.html
32. Ecks, S. Global pharmaceutical markets and corporate citizenship: The case of Novartis' anti-cancer drug Glivec. BioSocieties 3:165-181, 2008.
33. Médecins sans Frontières. US-Thailand Free-Trade Agreement: MSF Calls Thailand to Protect Access to Medicines in the Face of US Pressure. Press release, New York, 2006. http://www.doctorswithoutborders.org/pr/2006/01- 11-2006.cfm
34. Drahos, P. Developing countries and international property standard setting. J. World Intellect. Property 5:765-789, 2002.
35. Drezner, D. W. The semi-deviant case: TRIPS and public health. In All Politics Is Global: Explaining International Regulatory Regimes. Princeton University Press, Princeton, NJ, 2007.
36. Dur, A., and De Bievre, D. Inclusion without influence? NGOs in European trade policy. J. Public Policy 27:79-101, 2007. (Pubitemid 46151898)
37. Velasquez, G., and Boulet, P. Globalisation and Access to Medicines: Implications of the WTO/TRIPS Agreement. World Health Organization, Geneva, 1998.
38. Hogerzeil, H. V., et al. Is access to essential medicines as part of the fulfilment of the human right to health enforceable through the courts? Lancet 368:305-311, 2006. (Pubitemid 44067247)
39. Nunn, A., et al. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment. PLoS Med. 4(11):e305, 2007, doi: 10.1371/journal.pmed.0040305. (Pubitemid 350220533)
40. World Health Organization. A Summary Report from the Global Price Reporting Mechanism on Antiretroviral Drugs. Geneva, 2007. http://www.who.int/ hiv/amds/GPRMsummaryReportOct07.pdf
41. Attaran, A., and Gillespie-White, L. Do patents for antiretroviral drugs constrain access to HIV/AIDS treatment in Africa? JAMA 286:1886-1892, 2001. (Pubitemid 33010242)
42. Fink, C., and Reichenmiller, P. Tightening TRIPS: The Intellectual Property Provisions of Recent US Free Trade Agreements. Rep. No. Trade Note 20. World Bank, Washington, DC, 2005.
43. Roffe, P., and Spennemann, C. The impact of FTAs on public health policies and TRIPS flexibilities. J. Intellect. Property Manage. 1(1/2):75-93, 2006.
44. Doha World Trade Organization Ministerial. Declaration on the TRIPS Agreement and Public Health. Doha Declaration, WT/MIN(01)/DEC/2, November 20, 2001; adopted November 14, 2001. Doha, 2001.
45. Joint NGO Statement on TRIPS and Public Health Deal on Medicines: A "Gift" Bound in Red Tape. Joint NGO statement, September 10, 2003. http://www.cptech.org/ip/wto/p6/ngos09102003.html
46. Smith, D., and Bryant, J. H. Building the infrastructure for primary health care: An overview of vertical and integrated approaches. Soc. Sci. Med. 26:909-917, 1988.
47. Unger, J.-P., and Killingsworth, J. R. Selective primary health care: A critical review of methods and results. Soc. Sci. Med. 22(10):1001-1013, 1986. (Pubitemid 16029905)
48. Walsh, J. A., and Warren, K. S. Selective primary health care: An interim strategy for diseases control in developing countries. N. Engl. J. Med. 301(18):967-974, 1979. (Pubitemid 10204246)
49. Koivusalo, M., and Ollila, E. Making a Healthy World: Agencies, Actors, and Policies in International Health. Zed Books, London, 1997.
50. World Health Organization Commission on Macroeconomics and Health. Macroeconomics and Health: Investing in Health for Economic Development. World Health Organization, Geneva, 2001. http://whqlibdoc.who.int/publications/2001/ 924154550x.pdf
51. U.N. General Assembly. Declaration of Commitment on HIV/AIDS, August 2, 2001. A/RES/S-26/2. New York, 2001. http://www.un.org/ga/aids/docs/aress262.pdf
52. Lewis, M. Addressing the Challenge of HIV/AIDS: Macroeconomic, Fiscal, and Institutional Issues. Working Paper 58. Center for Global Development, Washington, DC, 2005.
53. World Health Organization. World Health Statistics. Geneva, 2008.
54. England, R. The dangers of diseases specific aid programmes. BMJ 335:565, 2008.
55. England, R. The writing is on the wall for UNAIDS. BMJ 336:1072, 2008.
56. Management Systems International. Enhancing Linkages with Vertical Health Funds: Country Case Studies of Ghana and Sierra Leone and a Comparative Analysis. USAID, Washington, DC, 2007.
57. Garret, L. The challenge of global health. Foreign Aff. 86(1):14-38, 2007.
58. McNeil, D. G. Gates Foundation's influence criticized. New York Times, February 16, 2008.
59. Donnelly, E. Proclaiming Jubilee: The debt and structural adjustment network. In Restructuring World Politics: Transnational Social Movements, Networks, and Norms, ed. S. Khagram, J. V. Riker, and K. Sikkink. University of Minnesota Press, Minneapolis, 2001.
60. Labonte, R., et al. Fatal Indifference: G8, Africa, and Global Health. International Research Development Centre, Ottawa, 2004.
61. Performance and Innovation Unit. Tackling the Diseases of Poverty: Meeting the Okinawa/Millennium Targets for HIV/AIDS, Tuberculosis, Malaria. Cabinet Office, London, 2001.
62. United Nations, UNAIDS, and World Health Organization. The United Nations Secretary General to Lead the Fight against AIDS. Joint press release. World Health Organization, Geneva, April 5, 2001. http://www.who.int/inf-pr-2001/en/ pr2001-19.html
63. HAI Europe, Health Gap Coalition, and ACT UP Paris. Public Interest NGOs Demand That the Global Health Fund Meets Poor Countries' Needs, Not Those of Industry. May 15, 2001. http://www.cptech.org/ip/health/who/ngos05152001.html
64. Pecoul, B. Open Letter to Members of the Board of Directors and Technical Review Panel of the Global Fund to Fight AIDS, Tuberculosis and Malaria. Médicins sans Frontières, Paris, 2002. http://www.cptech.org/ip/ health/fund/msf04182002.html (accessed April 1, 2009)
65. Ollila, E. Health-related public-private partnerships and the United Nations. In Global Social Governance: Themes and Prospects, ed. B. Deacon et al. Ministry for Foreign Affairs, Helsinki, 2004.
66. Zeltner, T., et al. Tobacco Company Strategies to Undermine Tobacco Control Activities at the World Health Organisation. Report of the Committee of Experts on Tobacco Industry Documents. World Health Organization, Geneva, July 2000.
67. Braithwaite, J., and Drahos, P. Global Business Regulation. Cambridge University Press, Cambridge, 1999.
68. G8. Growth and Responsibility in the World Economy. G8 summit declaration. Heiligendam, June 7, 2007. http://www.g-8.de/Webs/G8/EN/G8Summit/ SummitDocuments/summit-documents.html
69. European Union. Consultation on the elements of a global strategy and plan of action (A/PHI/IGWG/1/5): Comments by the European Union. In Intergovernmental Working Group on Public Health, Innovation, and Intellectual Property. WHO/PHI/2007.1. Member States Submissions to the IGWG Document A/PHI/IGWG/1/5. Secretariat on Public Health, Innovation and Intellectual Property. World Health Organization, Geneva, 2007.
70. Passarani, I. BEUC Position on the Future of Medicines in Europe. X/59/2007-23/10/2007.BEUC/European Consumers' Organisation, Brussels, 2007.
71. O'Harrow, R. Grass roots seeded by drugmaker. Washington Post, September 12, 2000.
72. Health Action International. Does the European Patient Forum Represent Patient or Industry Interests: A Case Study in the Need for Mandatory Financial Disclosure. Amsterdam, 2005.
73. da Silva, V. A., and Terrazas, F. V. Claiming the Right to Health in Brazilian Courts: The Exclusion of the Already Excluded. 2008. http://ssrn.com/abstract=1133620
74. Jurberg, C. Brazil probes pharmaceutical industry for building high cost drug demand. Intellect. Property Watch, August 8, 2008.
75. Wilpulpolprasert, S., et al. WHO's web-based public hearings hijacked by pharma? Lancet 370:1666, 2007.
76. Essential Action. Patients, Patents, and the Pharmaceutical Industry: The Pharmaceutical Industry Ties of the Organisation "Patients and Patents" and the Signers of the "Patient Declaration" on Medical Innovation and Access. Washington, DC, April 28, 2008.
77. Patient Declaration on Innovation and Access. http://www. patientsandpatents.com/index.php/us/positions/patient-declaration-on-medical- innovation
78. Patients Speak Out on Global Health and Innovation. Geneva, May 15, 2008. http://www.patientsandpatents.com/index.php/us/news-room/patients-speak-out-on- global-health-and-innovation
79. Herxheimer, A. Relationships between pharmaceutical industry and patients' organisations. BMJ 326:1208-1210, 2003. (Pubitemid 36649062)
80. International Policy Network. Civil Society Report on Intellectual Property, Innovation, and Public Health. London, 2006.
81. Sourcewatch. International Policy Network. http://www.sourcewatch.org/ index.php?title=International-Policy-Network